Literature DB >> 18793682

The opioid receptor antagonist naltrexone attenuates reinstatement of amphetamine drug-seeking in the rat.

Jenny Häggkvist1, Sara Lindholm, Johan Franck.   

Abstract

Amphetamine produces its rewarding effects by enhancing dopamine transmission in the mesocorticolimbic pathway. Several studies have also suggested the involvement of the endogenous opioid system in mediating the neurochemical and behavioural effects of amphetamine. The aim of this study was to investigate the effect of the unselective opioid receptor antagonist naltrexone (NTX) on reinstatement of amphetamine self-administration in the rat. Animals were trained to self-administer amphetamine under a fixed ratio 1 (FR1) schedule (0.1mg/kg/infusion). After receiving a stable drug intake the amphetamine was replaced with saline and the animals went through an extinction period. After reaching the extinction criteria, animals were pre-treated with NTX (0, 0.3, 1.0 and 3.0mg/kg, s.c.) 30min before giving a priming dose of amphetamine (0.5mg/kg s.c). To study the effects of NTX on operant behaviour, animals were trained to lever press for food pellets under a FR1 schedule of reinforcement. Results from the present study shows that a single injection of amphetamine reinstated self-administration behaviour. NTX (0.3 and 1.0mg/kg) significantly attenuated the amphetamine-induced reinstatement but NTX had no effect at any dose studied on food taking behaviour. These results show that NTX attenuates reinstatement of amphetamine self-administration in rats without suppressing general behaviour, implicating a functional role for opioid receptors in modulating amphetamine seeking behaviour.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18793682     DOI: 10.1016/j.bbr.2008.08.021

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  13 in total

Review 1.  Clinical safety of 1500 mg oral naltrexone overdose.

Authors:  Albert Stuart Reece
Journal:  BMJ Case Rep       Date:  2010-09-07

Review 2.  Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature.

Authors:  Kelly E Courtney; Lara A Ray
Journal:  Drug Alcohol Depend       Date:  2014-08-17       Impact factor: 4.492

Review 3.  Role of cues and contexts on drug-seeking behaviour.

Authors:  Christina J Perry; Isabel Zbukvic; Jee Hyun Kim; Andrew J Lawrence
Journal:  Br J Pharmacol       Date:  2014-07-02       Impact factor: 8.739

4.  The effects of lobeline and naltrexone on methamphetamine-induced place preference and striatal dopamine and serotonin levels in adolescent rats with a history of maternal separation.

Authors:  J J Dimatelis; V A Russell; D J Stein; W M Daniels
Journal:  Metab Brain Dis       Date:  2012-03-04       Impact factor: 3.584

5.  Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine.

Authors:  William W Stoops; Erika Pike; Lon R Hays; Paul E Glaser; Craig R Rush
Journal:  Pharmacol Biochem Behav       Date:  2014-11-29       Impact factor: 3.533

6.  Naltrexone decreases D-amphetamine and ethanol self-administration in rhesus monkeys.

Authors:  Corina Jimenez-Gomez; Gail Winger; Reginald L Dean; Daniel R Deaver; James H Woods
Journal:  Behav Pharmacol       Date:  2011-02       Impact factor: 2.293

7.  Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial.

Authors:  Valgerdur Runarsdottir; Ingunn Hansdottir; Thorarinn Tyrfingsson; Magnus Einarsson; Karen Dugosh; Charlotte Royer-Malvestuto; Helen Pettinati; Jag Khalsa; George E Woody
Journal:  J Addict Med       Date:  2017 May/Jun       Impact factor: 3.702

8.  The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.

Authors:  Lara A Ray; Spencer Bujarski; Kelly E Courtney; Nathasha R Moallem; Katy Lunny; Daniel Roche; Adam M Leventhal; Steve Shoptaw; Keith Heinzerling; Edythe D London; Karen Miotto
Journal:  Neuropsychopharmacology       Date:  2015-03-24       Impact factor: 7.853

9.  Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.

Authors:  Larissa J Mooney; Maureen P Hillhouse; Christie Thomas; Alfonso Ang; Gaurav Sharma; Garth Terry; Linda Chang; Robrina Walker; Madhukar Trivedi; David Croteau; Steven Sparenborg; Walter Ling
Journal:  J Addict Med       Date:  2016 Jul-Aug       Impact factor: 3.702

10.  Effects of amphetamine on the human brain opioid system--a positron emission tomography study.

Authors:  Joar Guterstam; Nitya Jayaram-Lindström; Simon Cervenka; J James Frost; Lars Farde; Christer Halldin; Johan Franck
Journal:  Int J Neuropsychopharmacol       Date:  2012-08-29       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.